Quinoxaline-Based Linear HCV NS3/4A Protease Inhibitors Exhibit Potent Activity against Drug Resistant Variants

[Image: see text] A series of linear HCV NS3/4A protease inhibitors was designed by eliminating the P2–P4 macrocyclic linker in grazoprevir, which, in addition to conferring conformational flexibility, allowed structure–activity relationship (SAR) exploration of diverse quinoxalines at the P2 positi...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:ACS Med Chem Lett
Prif Awduron: Rusere, Linah N., Matthew, Ashley N., Lockbaum, Gordon J., Jahangir, Muhammad, Newton, Alicia, Petropoulos, Christos J., Huang, Wei, Kurt Yilmaz, Nese, Schiffer, Celia A., Ali, Akbar
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Chemical Society 2018
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6047049/
https://ncbi.nlm.nih.gov/pubmed/30034602
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.8b00150
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg